Mar 11, 2025

Featuring perspectives from Dr Kevin S Hughes and Dr Mark Robson, including the following topics:

• Introduction (0:00)
• Optimal Approach to Genetic Testing for Patients with Localized Breast Cancer (BC) — Dr Hughes (10:22)
• Available Data with and Practical Application of PARP Inhibition as Adjuvant Therapy for Patients...

Mar 3, 2025

Featuring an interview with Dr Komal Jhaveri, including the following topics:

• Imlunestrant, an oral selective estrogen receptor degrader (SERD), with and without abemaciclib for ER-positive, HER2-negative advanced or metastatic breast cancer (0:00)
  • Jhaveri KL et al. Imlunestrant, an oral selective estrogen receptor...

Feb 14, 2025

Featuring slide presentations and related discussion from Dr Joyce O'Shaughnessy, Dr Mark Pegram and Prof Peter Schmid, including the following topics:

• Strategies to Identify Patients with HER2-Low and HER2-Ultralow Breast Cancer (0:00)
• Case: A woman in her mid 50s initially presenting with ER-positive, HER2 IHC...

Feb 8, 2025

Featuring an interview with Dr Seth Wander, including the following topics:

• Therapy selection after CDK4/6 inhibitor failure: A review of current and investigational treatment for HR-positive, HER2-negative breast cancer
  • Astore S et al. A therapeutic algorithm guiding subsequent therapy selection after CDK4/6...

Jan 31, 2025

Featuring an interview with Dr Seth Wander, including the following topics:

• The clinical utility of ESR1 mutations in HR-positive, HER2-negative advanced breast cancer
  • Grinshpun A et al. The clinical utility of ESR1 mutations in hormone receptor-positive, HER2-negative advanced breast cancer. Hematol Oncol Clin...